secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-04-18T23:59:59+00:00
Accession:  0001493152-23-012718
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma: compassionate use patient complete resolution of rare fungal infection with MAT2203; Phase 3 planned
--------------------------------------------------------------------------------

- Patient treated with MAT2203 achieved complete clinical resolution of R. mucilaginosa infection after 6 months and regained use of foot.
- MAT2203 was well-tolerated with no renal adverse effects; patient's renal function improved and remained at baseline.
- Prior IV-amphotericin B was discontinued due to electrolyte abnormalities and toxicities; MAT2203 allowed outpatient monitoring.
- Company in final stages of planning Phase 3 program for MAT2203 with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223012718/0001493152-23-012718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223012718/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer